Humana (NYSE:HUM) Given New $322.00 Price Target at Barclays

Humana (NYSE:HUM) had its price objective boosted by Barclays from $270.00 to $322.00 in a research note published on Friday morning,Benzinga reports. They currently have an equal weight rating on the insurance provider’s stock.

Several other brokerages have also commented on HUM. Morgan Stanley cut their price target on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Mizuho lifted their target price on Humana from $305.00 to $316.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 9th. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 target price on shares of Humana in a report on Wednesday, February 12th. JPMorgan Chase & Co. dropped their price target on Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 18th. Finally, Truist Financial boosted their price objective on Humana from $290.00 to $325.00 and gave the company a “hold” rating in a research note on Friday. Seventeen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $288.60.

Humana Stock Up 1.6 %

Humana stock opened at $294.97 on Friday. The stock has a market cap of $35.60 billion, a PE ratio of 29.65, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The stock’s fifty day moving average is $265.55 and its two-hundred day moving average is $270.35. Humana has a 1-year low of $213.31 and a 1-year high of $406.46.

Humana (NYSE:HUM) last issued its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, sell-side analysts expect that Humana will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date of this dividend is Friday, March 28th. Humana’s dividend payout ratio is presently 35.58%.

Hedge Funds Weigh In On Humana

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. grew its holdings in Humana by 15.8% during the fourth quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock worth $3,254,899,000 after acquiring an additional 1,751,857 shares during the period. Dodge & Cox boosted its position in shares of Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares in the last quarter. Pzena Investment Management LLC grew its stake in shares of Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after purchasing an additional 1,103,132 shares during the period. Geode Capital Management LLC increased its holdings in shares of Humana by 2.3% in the 4th quarter. Geode Capital Management LLC now owns 2,883,614 shares of the insurance provider’s stock valued at $729,658,000 after purchasing an additional 63,562 shares in the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Humana by 29.8% in the fourth quarter. Invesco Ltd. now owns 2,397,808 shares of the insurance provider’s stock valued at $608,348,000 after purchasing an additional 550,692 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.